SANUWAVE Health, Inc. — 2016 Form 10-K
Business and period: The filing covers the fiscal year ended December 31, 2016, with comparisons to 2015. SANUWAVE develops noninvasive acoustic shock-wave products. It had no products approved for U.S. commercial sale; revenue came primarily from international sales of orthoPACE devices and related applicators. Its lead U.S. candidate, dermaPACE, targets diabetic foot ulcers.
Financial performance and position
| Metric | 2016 | 2015 |
|---|---|---|
| Revenue | $1.376 million | $965,501 |
| Gross profit / margin | $810,934 / 59% | $680,539 / 70% |
| Research and development | $1.129 million | $2.173 million |
| General and administrative | $2.674 million | $2.735 million |
| Operating loss | $3.316 million | $4.438 million |
| Net loss | $6.439 million | $4.810 million |
| Net loss per share, basic and diluted | $0.06 | $0.08 |
| Cash used in operating activities | $3.199 million | $3.473 million |
- Revenue increased 43%, mainly from sales of 17 additional orthoPACE devices and higher applicator sales. Gross margin fell from 70% to 59% as devices represented a larger share of sales.
- The operating loss narrowed as operating expenses declined, including a 48% reduction in R&D. Net loss nevertheless increased 34%, principally due to a $2.224 million noncash warrant-valuation loss and higher interest expense.
- At year-end, cash was $133,571; current assets were $914,146 and current liabilities were $7.916 million, producing negative working capital of $7.002 million. Total liabilities were $7.916 million and stockholders’ deficit was $6.912 million. Accumulated deficit was $99.433 million.
- Operating cash outflow was partly offset by $3.208 million of financing cash inflows, including net proceeds of $1.597 million from a public offering and $1.528 million from a private placement. Cash declined by $19,359 during 2016.
- Related-party notes payable were $5.365 million net of discount, carried at 8% interest, and secured by a first lien on company assets. Although their stated maturity was extended to January 31, 2018, the filing says interest was in default as of January 1, 2017 and HealthTronics could call the notes; they were therefore classified as current.
Material developments, outlook, and risks
- dermaPACE studies: Across two sham-controlled studies involving 336 patients, the pre-specified 12-week wound-closure result was not statistically significant: 22.7% for dermaPACE versus 18.3% for control (p=0.320). Secondary analyses showed statistical significance at 20 weeks (35.47% versus 24.39%, p=0.027) and 24 weeks (37.8% versus 26.2%, p=0.023). The company reported no meaningful difference in adverse-event rates.
- The company submitted a de novo petition to the FDA on July 23, 2016, seeking Class II classification. Approval was pending at the filing date; management hoped for a decision in early 2017 and described U.S. commercialization as conditional on approval. The filing does not report an FDA approval.
- Management estimated operating cash use of $175,000–$225,000 per month during the first two quarters of 2017 and said additional capital was needed during or before the second quarter. Planned sources included strategic partnerships or licensing, equity, convertible securities, or debt. Financing was not assured and could materially dilute shareholders; management warned that failure to raise funds could lead to a U.S. bankruptcy filing.
- The independent auditor’s report and the financial statements disclose substantial doubt about the company’s ability to continue as a going concern. Management’s funding plans do not remove that uncertainty.
- Warrant-related financing creates material dilution and accounting volatility: the company recorded a $2.224 million noncash warrant revaluation loss, and 78.1 million warrants were outstanding at year-end. Common shares outstanding rose from 63.1 million to 137.2 million during 2016.
- International revenue and receivables were concentrated: two distributors generated 82% of 2016 revenue and represented 97% of year-end accounts receivable. The company also relied on single-source suppliers for most product components.
- Commercial execution depends on FDA authorization, reimbursement, market acceptance, and partnerships; the company had six full-time U.S. employees and said it lacked U.S. sales and marketing resources. It reported no material pending legal proceedings. Management assessed disclosure controls and internal control over financial reporting as effective; the auditor did not provide an opinion on internal-control effectiveness.
Investor verification priorities
- Check subsequent FDA filings and the actual outcome and timing of the dermaPACE de novo petition; distinguish the nonsignificant 12-week primary endpoint from later significant secondary analyses.
- Verify post-year-end liquidity, capital raises, cash burn, and whether the HealthTronics default was cured, waived, or called; assess repayment capacity for the secured related-party notes.
- Review the full warrant and convertible-security terms, including anti-dilution provisions, potential share issuance, and the effect on existing shareholders.
- Assess whether distributor concentration, collections, and supplier dependence changed after year-end, and whether international sales can support operating needs.
- Confirm the status of reimbursement, commercialization arrangements, and resources required for any U.S. launch.